FluoGuide A/S presents at BioStock Live

Copenhagen, Denmark, 14 October 2020 - FluoGuide A/S (“FluoGuide” or “the Company”) presents at BioStock Live on Thursday 15 October 2020 at 12.00 CEST.

Together with four other Life Science companies, FluoGuide will present at BioStock Live from their studio at Medicon Village in Lund to talk about the Company’s ongoing clinical trial of its lead product FG001, which will commence with a site inspection by the Danish Medicine Agency. The detailes about the clinical trial is presented in the interim report from Q2-2020 (page 6) released on 14 August 2020.

The event starts at 10:00 CEST and FluoGuide will begin presenting at 12:00 CEST. Please follow this link to watch the presentations. You can sign up for BioStock’s newsletter to receive a reminder for the event as well as other Life Science news.

 

For further information:
Morten Albrechtsen, CEO
M: +45 24 25 62 66
ma@fluoguide.com

 

About FluoGuide
FluoGuide’s primary focus is to maximize surgical outcomes in oncology. The Company’s first product, FG001, is designed to improve surgical precision by illuminating cancer cells intraoperatively. The improved precision enabled by FluoGuide’s products has a dual benefit – it reduces both the frequency of local recurrence post-surgery and lessens surgical sequelae. Ultimately, these improvements will improve a patient’s chance of achieving a complete cure and will lower system-wide healthcare costs. The Company is conducting a proof-of-concept clinical study (phase I/II) to demonstrate the effect of FG001 in patients with high grade glioma.

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 954904.

Tags:

About Us

FluoGuide A/S develops surgical solutions that is expected to reduce suffering for the patient and increases the likelihood of cure as well as reducing costs for the health care system. The first product is the compound FG001, which lights up the cancer and its invasive growth into the surrounding tissue. Preclinical studies have demonstrated the potential of FG001 to vastly improve the likelihood of performing radical surgery (removal of all cancer) and thereby improving outcome and survival. FluoGuide is initially focused on glioblastoma (brain tumor) but the Company plan to expand its business to other solid tumors. Market launch of FG001 in a first country is expected in 2022/2023.

Subscribe